Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRS047
MIFTS: 56

Prostatitis

Categories: Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Prostatitis

About this section

MalaCards integrated aliases for Prostatitis:

Name: Prostatitis 12 74 54 43 15 17 71

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:14654
ICD9CM 34 601.9
MeSH 43 D011472
NCIt 49 C26866
SNOMED-CT 67 9713002
ICD10 32 N41.9
UMLS 71 C0033581
Sources

Summaries for Prostatitis

About this section
MalaCards based summary : Prostatitis is related to prostatic hyperplasia, benign and adenosquamous prostate carcinoma, and has symptoms including prostatism An important gene associated with Prostatitis is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Acetaminophen and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and t cells, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Increased viability with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Prostatitis is inflammation of the prostate gland. Prostatitis is classified into acute, chronic,... more...

Sources

Related Diseases for Prostatitis

About this section

Diseases related to Prostatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2111)
# Related Disease Score Top Affiliating Genes
1 prostatic hyperplasia, benign 34.7 SERPINA3 KLK3 ACP3
2 adenosquamous prostate carcinoma 34.6 NKX3-1 KLK3
3 prostatic adenoma 34.6 SERPINA3 KLK3 ADRA1A
4 prostate disease 34.3 SERPINA3 PCA3 KLK3 ACP3
5 prostatic hypertrophy 34.1 SERPINA3 KLK3 ADRA1A ACP3
6 prostatic acinar adenocarcinoma 33.9 NKX3-1 KLK3
7 kaposi sarcoma 32.6 TP53 IL6 CXCL8 CASP3
8 suppression of tumorigenicity 12 32.4 TP53 TNF SERPINA3 PTGS2 PCA3 NKX3-1
9 penile disease 32.2 TP53 TNF TGFB1 IL6
10 prostate cancer 32.0 VDR TP53 TNF TGFB1 SERPINA3 PTGS2
11 sarcoma 32.0 TP53 SERPINA3 PTGS2 IL6 CXCL8 CASP3
12 impotence 32.0 PRL KLK3 ADRA1A
13 colorectal adenoma 31.5 VDR TP53 TNF PTGS2 IL6
14 urinary tract obstruction 31.4 TNF TGFB1 PTGS2 KLK3
15 sexual disorder 31.4 SERPINA3 PRL KLK3 ADRA1A
16 chronic kidney disease 31.4 VDR TNF TGFB1 SERPINA3 IL6 IL1B
17 pyuria 31.3 KLK3 IL6 CXCL8
18 cystitis 31.3 TP53 TNF PTGS2 IL6 CXCL8
19 hydronephrosis 31.2 TGFB1 KLK3 IL6 CXCL8
20 pulmonary tuberculosis 31.2 VDR TNF IL6 IL1B IL10
21 severe combined immunodeficiency 31.1 TGFB1 PTGS2 IL6 IL10 CXCR4 CASP3
22 neuroblastoma 31.0 TP53 TNF PTGS2 IL6 IL1B CXCR4
23 skin carcinoma 31.0 VDR TP53 PTGS2 CASP3
24 ureteral obstruction 31.0 TP53 TGFB1 PTGS2 IL10
25 urethritis 30.9 TNF KLK3 IL6 IL1B CXCL8
26 alopecia 30.9 VDR TNF PRL IL1B
27 spinal cord injury 30.9 TNF IL6 CXCL8 CASP3
28 female breast cancer 30.9 TP53 TNF KLK3
29 osteoarthritis 30.9 TNF TGFB1 PTGS2 IL6 IL1B CXCL8
30 chlamydia 30.9 TNF IL6 IL1B IL10 CXCL8
31 pain agnosia 30.9 PTGS2 IL6 IL1B ADRA1A
32 clear cell adenocarcinoma 30.8 TP53 KLK3 ACP3
33 villous adenoma 30.8 TP53 KLK3 ACP3
34 osteogenic sarcoma 30.8 VDR TP53 TNF IL6 CASP3
35 bone resorption disease 30.8 VDR TNF SERPINA3 IL6 IL1B
36 urolithiasis 30.7 VDR IL6 IL1B
37 orchitis 30.7 TNF IL6 IL1B IL10
38 osteonecrosis 30.7 TNF IL1B IL10
39 neutropenia 30.6 TP53 TNF IL6 IL1B IL10 CXCR4
40 acute cystitis 30.6 TNF SERPINA3 KLK3 IL6 IL1B IL10
41 thrombophlebitis 30.6 TNF TGFB1 PROS1
42 exanthem 30.6 TNF IL6 IL1B IL10 CXCL8
43 melioidosis 30.5 TNF IL6 IL10
44 varicocele 30.5 TP53 TNF PRL IL6 CASP3
45 mucositis 30.5 TGFB1 IL1B IL10 CASP3
46 multicentric carpotarsal osteolysis syndrome 30.5 TNF IL6 IL1B
47 bone disease 30.5 VDR TNF SERPINA3 IL6 IL1B CXCL8
48 purpura 30.5 TNF PROS1 IL6 IL10
49 diarrhea 30.5 TNF TGFB1 IL6 IL1B IL10 CXCL8
50 acute pyelonephritis 30.5 IL6 IL10 CXCL8

Comorbidity relations with Prostatitis via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Epididymo-Orchitis Prostate Calculus
Prostate Cancer Prostatic Hypertrophy
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatitis:



Diseases related to Prostatitis
Sources

Symptoms & Phenotypes for Prostatitis

About this section

UMLS symptoms related to Prostatitis:


prostatism

GenomeRNAi Phenotypes related to Prostatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.81 TP53
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.81 ADRA1A CASP3 CXCR4 IL10 IL1B TNF
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.81 TP53
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.58 ADRA1A CASP3 CXCL8 CXCR4 IL10 IL1B
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.58 ADRA1A CASP3 CXCL8 CXCR4 IL10 IL1B
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.58 TP53
7 Increased viability with paclitaxel GR00179-A-1 8.65 CASP3

MGI Mouse Phenotypes related to Prostatitis:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 ADRA1A CASP3 CXCR4 IL10 IL1B IL6
2 behavior/neurological MP:0005386 10.39 ACP3 ADRA1A CASP3 IL10 IL6 NKX3-1
3 homeostasis/metabolism MP:0005376 10.39 ADRA1A CASP3 CXCR4 IL10 IL1B IL6
4 endocrine/exocrine gland MP:0005379 10.35 ACP3 CASP3 CXCR4 IL10 IL6 MSMB
5 integument MP:0010771 10.35 ACP3 CASP3 CXCR4 IL10 IL1B IL6
6 immune system MP:0005387 10.27 CASP3 CXCR4 IL10 IL1B IL6 MSMB
7 hematopoietic system MP:0005397 10.26 CASP3 CXCR4 IL10 IL1B IL6 PROS1
8 digestive/alimentary MP:0005381 10.25 CASP3 CXCR4 IL10 IL6 NKX3-1 PTGS2
9 muscle MP:0005369 10.21 ADRA1A CASP3 CXCR4 IL10 IL6 KLK3
10 neoplasm MP:0002006 10.18 ACP3 CXCR4 IL10 IL1B IL6 MSMB
11 craniofacial MP:0005382 10.16 CASP3 CXCR4 IL10 IL1B TGFB1 TNF
12 nervous system MP:0003631 10.15 CASP3 CXCR4 IL10 IL1B IL6 PRL
13 liver/biliary system MP:0005370 10.06 IL10 IL6 PRL PROS1 PTGS2 TGFB1
14 reproductive system MP:0005389 9.97 ACP3 CASP3 CXCR4 IL10 IL6 MSMB
15 no phenotypic analysis MP:0003012 9.87 CASP3 IL10 NKX3-1 PROS1 PTGS2 TNF
16 renal/urinary system MP:0005367 9.86 ADRA1A CASP3 CXCR4 IL6 PTGS2 TGFB1
17 respiratory system MP:0005388 9.56 CASP3 CXCR4 IL10 IL6 PTGS2 TGFB1
18 skeleton MP:0005390 9.36 CASP3 CXCR4 IL10 IL1B IL6 NKX3-1
Sources

Drugs & Therapeutics for Prostatitis

About this section

Drugs for Prostatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
3
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
4
Sodium citrate Approved, Investigational Phase 4 68-04-2
5
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
6
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
7
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
8
BCG vaccine Investigational Phase 4
9 Acidophilus Phase 4
10 Pharmaceutical Solutions Phase 4
11 Antimetabolites Phase 4
12 Anesthetics Phase 4
13 Immunologic Factors Phase 4
14 Adjuvants, Immunologic Phase 4
15 Alkylating Agents Phase 4
16 Vaccines Phase 4
17 Mitomycins Phase 4
18 Neurotransmitter Agents Phase 4
19 Analgesics Phase 4
20 abobotulinumtoxinA Phase 4
21 Botulinum Toxins, Type A Phase 4
22 Cholinergic Agents Phase 4
23 Anti-Anxiety Agents Phase 4
24 Psychotropic Drugs Phase 4
25 Anticonvulsants Phase 4
26 Botulinum Toxins Phase 4
27 Citrate Phase 4
28 Phosphodiesterase 5 Inhibitors Phase 4
29 Phosphodiesterase Inhibitors Phase 4
30 Vasodilator Agents Phase 4
31 Sildenafil Citrate Phase 4 171599-83-0
32 Excitatory Amino Acid Antagonists Phase 4
33 Antiparasitic Agents Phase 4
34 Carboxymethylcellulose Sodium Phase 4
35 Antiprotozoal Agents Phase 4
36 Antimalarials Phase 4
37
Pregabalin Approved, Investigational Phase 3 148553-50-8 5486971
38
Alfuzosin Approved, Investigational Phase 3 81403-80-7 2092
39
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
40
Cefazolin Approved Phase 3 25953-19-9 656510 33255
41
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
42
Dutasteride Approved, Investigational Phase 3 164656-23-9 152945 6918296
43
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
44 calcium channel blockers Phase 3
45 Phytosterol Phase 3
46 Adrenergic alpha-Antagonists Phase 3
47 Adrenergic Agents Phase 3
48 Adrenergic Antagonists Phase 3
49 Adrenergic alpha-1 Receptor Antagonists Phase 3
50 5-alpha Reductase Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 Chronic Bacterial Prostatitis: Efficacy of Short-lasting Antibiotic Therapy With Prulifloxacin (Unidrox®) in Association With Saw Palmetto Extract, Lactobacillus Sporogens and Arbutin (Lactorepens®) Completed NCT02130713 Phase 4 Third generation fluoroquinolone
2 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward Completed NCT02246361 Phase 4
3 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
4 Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
5 Local Anesthesia for Prostate Biopsy: Effects on Pain Control, Quality of Life, and Surgical Intervention Completed NCT00422708 Phase 4
6 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
7 Effectiveness 0f Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia) Suspended NCT00194636 Phase 4
8 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
9 Efficacy of Gralise® for Chronic Pelvic Pain Terminated NCT01678911 Phase 4 Gralise
10 Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
11 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
12 A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
13 Randomized, Open-Labeled Study of Prophylactic Vs. Therapeutic Use of Uroxatrol to Determine Improvements in Urinary Morbidity Following Men Undergoing Prostate Brachytherapy Unknown status NCT00201630 Phase 3 Uroxatrol (drug)
14 A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to That of Ciprofloxacin in the Treatment of Chronic Prostatitis Completed NCT00236808 Phase 3 levofloxacin
15 A Double Blind, Sham Controlled Trial Evaluating the Efficacy of Acupuncture in Relieving Symptoms of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome Completed NCT00260637 Phase 2, Phase 3
16 Prospective, Multinational, Multicenter, Non-Comparative, Open Study With a 6 Months Follow-up Period to Demonstrate the Efficacy and Safety of Oral Levofloxacin 500 mg Once Daily in the Treatment of Chronic Bacterial Prostatitis (CBP) Completed NCT00277511 Phase 3 Levofloxacin
17 Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome Completed NCT00919893 Phase 3 Cernilton;Placebo
18 A Multicenter, Double-Blind, Phase 3B Study to Compare the Safety and Clinical Efficacy of Levofloxacin in 750mg for 2 Weeks and Levofloxacin 750mg for 3 Weeks to That of Levofloxacin 500mg for 4 Weeks in the Treatment of Chronic Prostatitis Completed NCT00402688 Phase 3 levofloxacin;levofloxacin;levofloxacin
19 A Randomized Clinical Trial to Evaluate the Efficacy and Safety of 10mg Alfuzosin in the Treatment of Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) in Recently-Diagnosed and/or Newly-Symptomatic Alpha-blocker Naïve Patients Completed NCT00103402 Phase 3 Alfuzosin;Placebo
20 A National, Multicentric, Randomised, Controlled Trial. Applications of a Critical Pathway Using Levofloxacin for the Management of Patients With Abnormal PSA. Completed NCT00169585 Phase 3 Levofloxacin oral tablets
21 Effects of Proxelan Somministration in Patients With Chronic Prostatitis Cat. IIa NIH: Pilot Study Recruiting NCT03629769 Phase 3 Proxelan
22 Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer: a Phase III Randomized Trial Recruiting NCT03862170 Phase 3 Ciprofloxacin;Cefazolin
23 Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
24 A Multi-center Randomized Placebo Controlled Trial Evaluating the Efficacy of JALYN in Improving Symptoms in Men Diagnosed With Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3 Jalyn;Placebo
25 Prospective, Randomized, Open Label Phase 3 Study of the Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin for Treatment of Patients With Fluoroquinolone-susceptible Multidrugresistant-‐Tuberculosis (MDR-TB) Withdrawn NCT02975570 Phase 3 Delamanid;Linezolid;Levofloxacin;Pyrazinamide;WHO MDR-TB regimen
26 Prospective, Randomized, Partially Blinded, Phase 3 Study of the Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine for Treatment of Patients With MDR-TB Withdrawn NCT03828201 Phase 3 Delamanid;Levofloxacin;Bedaquiline;Clofazimine;Linezolid
27 Laparoscopic Prostatectomy for Chronic Prostatitis Unknown status NCT00775515 Phase 2
28 A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00740779 Phase 2 Silodosin 8 mg;Placebo;Silodosin 4 mg
29 A Phase 2, 16 Week, Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel Group Proof-Of-Concept Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis Completed NCT00826514 Phase 2 Tanezumab;Placebo
30 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00701311 Phase 2 CC-10004
31 A Double-Blind, Randomized, Placebo-Controlled Trial of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Prostatitis Completed NCT00236990 Phase 2 pentosan polysulfate sodium
32 A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of CP/CPPS Completed NCT01391338 Phase 2 ASP3652;Placebo
33 Evaluation of the Safety and Tolerability of Transurethral Alcohol Injection for the Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
34 Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma Completed NCT02017353 Phase 2
35 Pilot Study of Influence of Hyaluronic Acid (HA) on Bacillus Calmette-Guérin (BCG) Local Side Effects Completed NCT02207608 Phase 2 Hyaluronic Acid;BCG (Immucist®)
36 Phase II Placebo Controlled Trial of Preoperative Lycopene Supplementation in Prostate Cancer Patients Completed NCT00450749 Phase 2 lycopene
37 A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome Completed NCT00362752 Phase 2 Norfloxacin;Placebo
38 A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL) Recruiting NCT03576378 Phase 1, Phase 2 BrentuximabVedotin (BV)
39 Evaluation of the Efficacy and Safety of Prulifloxacin vs Levofloxacin in the Treatment of Chronic Bacterial Prostatitis. Active, not recruiting NCT03201796 Phase 2 Prulifloxacin 600 mg;Levofloxacin 500mg
40 Use of Autologous Adipose-Derived Stem/Stromal Cells In Symptomatic Benign Prostate Hypertrophy Active, not recruiting NCT02961114 Phase 1, Phase 2
41 A Phase II Randomized Controlled Trial of a Supplement Containing Quercetin, Bromelain and Papain on Reducing the Severity of Radiation-Induced Prostatitis Not yet recruiting NCT04252625 Phase 2 Prosta-Q;Placebo
42 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
43 A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Terminated NCT03500159 Phase 2 AQX-1125 200 mg;Placebo
44 A Prospective Pilot Study to Evaluate the Safety and Efficacy of Botox™ for the Treatment of Men Diagnosed With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Terminated NCT00529386 Phase 1 Botox
45 Efficacy Study of Tamsulosin and Tolterodine Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Lower Urinary Tract Symptoms Unknown status NCT00913315 tolterodine;tamsulosin;placebo
46 The Efficacy of Extracorporal Shock Wave Therapy on Symptoms Relief in Patients With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830
47 Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation A Double-Blind, Placebo-Controlled, Fixed-Dose,Randomized Controlled Study Unknown status NCT00656552 Early Phase 1 Escitalopram
48 Impact of Selective Reporting of Antibiotic Susceptibility Test Results in Urinary Tract Infections in the Outpatient Setting: a Protocol for a Pragmatic, Prospective Quasi-experimental Trial Unknown status NCT03612297
49 Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT01843946
50 Non-interventional (Observational) Study of the Administration of Levolet® R, Film-coated Tablets (Dr. Reddy's Laboratories Ltd., India) in Adults With Chronic Prostatitis in Routine Clinical Practice Completed NCT02711943 Levofloxacin 500

Search NIH Clinical Center for Prostatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ciprofloxacin

Cochrane evidence based reviews: prostatitis

Sources

Genetic Tests for Prostatitis

About this section
Sources

Anatomical Context for Prostatitis

About this section

MalaCards organs/tissues related to Prostatitis:

40
Prostate, Testes, T Cells, Spinal Cord, Kidney, Brain, Neutrophil
Sources

Publications for Prostatitis

About this section

Articles related to Prostatitis:

(show top 50) (show all 5715)
# Title Authors PMID Year
1
Association between periodontal disease and prostate-specific antigen levels in chronic prostatitis patients. 54 61
20450358 2010
2
[Clinical analysis of benign prostate hyperplasia with prostatitis]. 61 54
20448364 2010
3
Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. 61 54
20177031 2010
4
Antibacterial therapy improves the effectiveness of prostate cancer detection using prostate-specific antigen in patients with asymptomatic prostatitis. 54 61
19548108 2010
5
Crucial role of interferon-gamma in experimental autoimmune prostatitis. 61 54
20096883 2010
6
Is it possible to predict sepsis, the most serious complication in prostate biopsy? 54 61
20224265 2010
7
Prostate specific antigen, pelvic pain and prostatitis--time for a new paradigm? 54 61
19524944 2009
8
Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy. 54 61
19725275 2009
9
Management of elevated prostate-specific antigen in men with nonbacterial chronic prostatitis. 61 54
19570492 2009
10
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. 61 54
19603556 2009
11
Impact of vitamin D receptor activity on experimental autoimmune prostatitis. 61 54
19269787 2009
12
Influence of inflammation and aging on macrophage inhibitory cytokine-1 gene expression in rat ventral prostate. 54 61
18929399 2009
13
Incidence of histological prostatitis and its correlation with PSA density. 61 54
19936177 2009
14
Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). 54 61
19111800 2009
15
[Wardenafil in combined treatment of patients with chronic bacterial prostatitis]. 54 61
19256057 2008
16
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. 61 54
18668524 2008
17
Control of autoimmune diseases by the vitamin D endocrine system. 61 54
18594491 2008
18
Prevalence of delayed clinician response to elevated prostate-specific antigen values. 61 54
18380989 2008
19
The issue of prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis. 61 54
18336465 2008
20
PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. 61 54
17637759 2008
21
Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatitis. 54 61
18362491 2008
22
Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice. 54 61
18836536 2008
23
Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection. 54 61
17695414 2007
24
Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). 61 54
17241782 2007
25
Serum prostate-specific antigen levels in Middle Eastern men with subclinical prostatitis. 54 61
17159365 2007
26
Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms. 61 54
17300876 2007
27
Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions. 61 54
18595241 2007
28
The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. 54 61
17111077 2007
29
Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. 61 54
17142748 2006
30
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. 61 54
16890703 2006
31
Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer. 54 61
16882055 2006
32
A sensitive proximity ligation assay for active PSA. 54 61
16800738 2006
33
Dealing with non-cancerous findings on prostate biopsy. 54 61
16630522 2006
34
Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies? 61 54
16401916 2006
35
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer. 54 61
16502048 2006
36
The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. 54 61
16385194 2006
37
Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk. 61 54
17318358 2006
38
Pharmacological treatment for premature ejaculation. 54 61
16212722 2005
39
Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. 61 54
15993362 2005
40
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. 54 61
15947609 2005
41
[Asymptomatic prostatitis: a frequent cause of raising PSA]. 61 54
16209120 2005
42
Pure prostatic papillary adenocarcinoma with ductal features. 54 61
15852679 2005
43
The vicious cycling: bicycling related urogenital disorders. 54 61
15716187 2005
44
Ability of PSA-positive circulating macrophages to detect prostate cancer. 54 61
15389786 2005
45
Effect of NIH-IV prostatitis on free and free-to-total PSA. 54 61
15548444 2004
46
PSA decrease after levofloxacin therapy in patients with histological prostatitis. 61 54
15693428 2004
47
[Effect of inflammatory chronic pelvic pain syndrome on the levels of prostatic specific antigen]. 54 61
15638019 2004
48
Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: a new approach to noninvasive diagnosis of prostate cancer. 61 54
15636686 2004
49
Application of serum PSA to identify acute bacterial prostatitis in patients with fever of unknown origin or symptoms of acute pyelonephritis. 54 61
15264238 2004
50
Prostate carcinoma among men with human immunodeficiency virus infection. 54 61
15241826 2004
Sources

Variations for Prostatitis

About this section
Sources

Expression for Prostatitis

About this section
Search GEO for disease gene expression data for Prostatitis.
Sources

Pathways for Prostatitis

About this section

Pathways related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.1 TP53 TNF TGFB1 SERPINA3 PTGS2 PROS1
2
ERK Signaling 63
Show member pathways
 13.89 TP53 TNF TGFB1 PTGS2 IL6 IL1B
3
PEDF Induced Signaling 63
Show member pathways
 13.75 TP53 TNF TGFB1 PTGS2 PRL IL6
4
TGF-Beta Pathway 63
Show member pathways
 13.6 TP53 TNF TGFB1 PRL IL6 IL1B
5
Akt Signaling 63
Show member pathways
 13.49 TP53 TNF TGFB1 IL6 IL1B IL10
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.42 TP53 TNF TGFB1 PTGS2 PRL IL6
7
PAK Pathway 63
Show member pathways
 13.37 TNF TGFB1 IL6 IL1B IL10 CXCR4
8
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.15 TP53 TNF TGFB1 IL6 IL1B IL10
9
PI3K-Akt signaling pathway 36
Show member pathways
 13.05 TP53 TNF PTGS2 PRL IL6 CASP3
10
Human cytomegalovirus infection 36
Show member pathways
 13.02 TP53 TNF PTGS2 IL6 IL1B CXCR4
11
Allograft rejection 1 36
Show member pathways
 12.91 TNF TGFB1 IL6 IL1B IL10 CXCR4
12
Measles 36
Show member pathways
 12.89 TP53 TNF IL6 IL1B CXCL8 CASP3
13
Pathways in cancer 36
12.87 TP53 TGFB1 PTGS2 NKX3-1 KLK3 IL6
14
Herpes simplex virus 1 infection 36
12.84 TP53 TNF IL6 IL1B CASP3
15
MAPK signaling pathway 36 1
12.82 TP53 TNF TGFB1 IL1B CASP3
16
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.78 TNF PTGS2 IL6 IL1B CXCL8
17
4-1BB Pathway 63
Show member pathways
 12.73 TP53 TNF IL1B CXCR4 CASP3
18
T cell receptor signaling pathway 36
Show member pathways
 12.67 TNF TGFB1 IL6 IL1B IL10
19
Th17 cell differentiation 36
Show member pathways
 12.66 TNF TGFB1 IL6 IL1B IL10
20
Immune response IL-23 signaling pathway 22
Show member pathways
 12.66 TP53 TNF IL6 IL1B IL10
21
NF-kappaB Signaling 4
12.63 TNF PTGS2 IL1B IL10 CXCR4
22
Shigellosis 36
12.44 TP53 TNF IL1B CXCL8
23
IL-17 Family Signaling Pathways 64
Show member pathways
 12.44 TNF PTGS2 IL6 IL1B CXCL8 CASP3
24
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.43 TNF IL6 IL10 CXCR4 CXCL8
25
Toll Comparative Pathway 63
Show member pathways
 12.43 TP53 TNF PTGS2 IL6 IL1B CXCL8
26
Folate Metabolism 1
Show member pathways
 12.43 TP53 TNF SERPINA3 PTGS2 IL6 IL1B
27
Salmonella infection (KEGG) 36
12.4 TNF IL6 IL1B CXCL8 CASP3
28
Human T-cell leukemia virus 1 infection 36
12.39 TP53 TNF TGFB1 IL6
29
Translation Non-genomic (rapid) action of Androgen Receptor 22
Show member pathways
 12.37 TP53 TGFB1 KLK3 IL6
30
Proteoglycans in cancer 36
12.36 TP53 TNF TGFB1 CASP3
31
Pathogenic Escherichia coli infection 36
12.36 TNF IL6 IL1B CXCL8 CASP3
32
Toxoplasmosis 36
Show member pathways
 12.35 TNF TGFB1 PTGS2 IL1B IL10 CASP3
33
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.34 TP53 TNF TGFB1 IL6 IL1B IL10
34
C-type lectin receptor signaling pathway 36
Show member pathways
 12.31 TNF PTGS2 IL6 IL1B IL10
35
NOD-like receptor signaling pathway 36
12.3 TNF IL6 IL1B CXCL8
36
Tuberculosis 36
12.28 VDR TNF TGFB1 IL6 IL1B IL10
37
Colorectal Cancer Metastasis 63
12.27 TP53 TNF TGFB1 PTGS2 IL6 CASP3
38
Bacterial infections in CF airways 22
Show member pathways
 12.26 TNF IL6 IL1B CXCL8
39
Cellular senescence (KEGG) 36
12.22 TP53 TGFB1 IL6 CXCL8
40
Alzheimers Disease 1
12.2 TP53 TNF IL1B CASP3
41
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.19 TNF NKX3-1 IL6 IL1B IL10 CXCL8
42
Yersinia infection 36
12.13 TNF IL6 IL1B IL10 CXCL8
43
TNF signaling pathway 36
12.1 TNF PTGS2 IL6 IL1B CASP3
44
Senescence and Autophagy in Cancer 1
12.07 TP53 TGFB1 IL6 IL1B CXCL8
45
IL27-mediated signaling events 1
Show member pathways
 12.06 TNF TGFB1 IL6 IL1B IL10
46
NF-kappa B signaling pathway 36
12.02 TNF PTGS2 IL1B CXCL8
47
AGE-RAGE signaling pathway in diabetic complications 36
11.99 TNF TGFB1 IL6 IL1B CXCL8 CASP3
48
Rheumatoid arthritis 36
11.97 TNF TGFB1 IL6 IL1B CXCL8
49
Glucocorticoid receptor regulatory network 1
11.91 TP53 PRL IL6 CXCL8
50
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.87 TNF PTGS2 CXCL8 CASP3
Sources

GO Terms for Prostatitis

About this section

Cellular components related to Prostatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF TGFB1 SERPINA3 PROS1 PRL MSMB
2 extracellular space GO:0005615 9.4 TNF TGFB1 SERPINA3 PROS1 PRL MSMB
3 platelet alpha granule lumen GO:0031093 9.33 TGFB1 SERPINA3 PROS1

Biological processes related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.35 VDR TGFB1 PRL IL6 IL1B IL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 VDR TP53 TNF TGFB1 NKX3-1 IL6
3 positive regulation of transcription, DNA-templated GO:0045893 10.16 TP53 TNF TGFB1 NKX3-1 IL6 IL1B
4 positive regulation of cell proliferation GO:0008284 10.13 TGFB1 PTGS2 PRL NKX3-1 IL6 IL1B
5 immune response GO:0006955 10.11 TNF IL6 IL1B IL10 CXCR4 CXCL8
6 positive regulation of apoptotic process GO:0043065 10.08 TP53 TNF TGFB1 PTGS2 IL6 CASP3
7 positive regulation of gene expression GO:0010628 10.08 VDR TP53 TNF TGFB1 NKX3-1 IL6
8 negative regulation of gene expression GO:0010629 10.06 VDR TP53 TNF TGFB1 NKX3-1
9 response to drug GO:0042493 10.04 TP53 TGFB1 PTGS2 IL10 CASP3 ADRA1A
10 regulation of cell proliferation GO:0042127 10.02 TP53 TNF TGFB1 PTGS2
11 leukocyte migration GO:0050900 10.01 TNF TGFB1 PROS1 IL1B
12 positive regulation of protein phosphorylation GO:0001934 10.01 TNF TGFB1 NKX3-1 IL1B
13 aging GO:0007568 10 TGFB1 PTGS2 IL10 ADRA1A
14 response to lipopolysaccharide GO:0032496 9.99 PTGS2 IL1B IL10 CASP3
15 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TNF TGFB1 IL6 IL1B
16 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.92 TNF TGFB1 PTGS2 IL6
17 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 TNF NKX3-1 IL6 IL1B IL10
18 inflammatory response GO:0006954 9.92 TNF TGFB1 SERPINA3 PTGS2 IL6 IL1B
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 TNF PTGS2 IL6
20 cellular response to organic cyclic compound GO:0071407 9.89 TNF TGFB1 IL1B CASP3
21 positive regulation of neuron apoptotic process GO:0043525 9.88 TP53 TNF CASP3
22 positive regulation of interleukin-6 production GO:0032755 9.88 TNF IL6 IL1B
23 cellular response to drug GO:0035690 9.88 TP53 NKX3-1 IL1B CXCR4
24 response to organic substance GO:0010033 9.88 TNF TGFB1 PTGS2 IL10 CASP3
25 cellular response to lipopolysaccharide GO:0071222 9.88 VDR TNF IL6 IL1B IL10 CXCL8
26 negative regulation of fat cell differentiation GO:0045599 9.86 TNF TGFB1 IL6
27 positive regulation of cell division GO:0051781 9.85 TGFB1 NKX3-1 IL1B
28 negative regulation of cell cycle GO:0045786 9.85 TGFB1 PTGS2 CASP3
29 positive regulation of epithelial to mesenchymal transition GO:0010718 9.85 TGFB1 IL6 IL1B
30 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 TNF PTGS2 IL1B
31 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TNF TGFB1 IL1B
32 protein kinase B signaling GO:0043491 9.81 TNF TGFB1 NKX3-1 IL1B
33 negative regulation of neurogenesis GO:0050768 9.8 TNF IL6 IL1B
34 positive regulation of JAK-STAT cascade GO:0046427 9.8 TNF PRL IL6 IL10
35 positive regulation of glial cell proliferation GO:0060252 9.79 TNF IL6 IL1B
36 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.77 TNF IL1B IL10
37 response to glucocorticoid GO:0051384 9.77 TNF PTGS2 IL6 IL10 CASP3
38 positive regulation of neuroinflammatory response GO:0150078 9.75 TNF IL6 IL1B
39 negative regulation of lipid storage GO:0010888 9.73 TNF IL6
40 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.73 TP53 TGFB1 IL6
41 positive regulation of vascular endothelial growth factor production GO:0010575 9.73 TGFB1 PTGS2 IL6 IL1B
42 response to salt stress GO:0009651 9.72 TP53 TNF
43 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
44 endothelial cell apoptotic process GO:0072577 9.72 TNF IL10
45 negative regulation of neuroblast proliferation GO:0007406 9.72 TP53 TGFB1
46 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.72 TP53 TNF TGFB1
47 positive regulation of mononuclear cell migration GO:0071677 9.7 TNF TGFB1
48 positive regulation of prostaglandin biosynthetic process GO:0031394 9.7 PTGS2 IL1B
49 negative regulation of cytokine production involved in immune response GO:0002719 9.7 TNF IL10
50 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.68 TNF NKX3-1

Molecular functions related to Prostatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 VDR TP53 TNF TGFB1 SERPINA3 PTGS2
2 cytokine activity GO:0005125 9.1 TNF TGFB1 IL6 IL1B IL10 CXCL8
Sources

Sources for Prostatitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....